JP2019516733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516733A5 JP2019516733A5 JP2018560759A JP2018560759A JP2019516733A5 JP 2019516733 A5 JP2019516733 A5 JP 2019516733A5 JP 2018560759 A JP2018560759 A JP 2018560759A JP 2018560759 A JP2018560759 A JP 2018560759A JP 2019516733 A5 JP2019516733 A5 JP 2019516733A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oxo
- pyrido
- trifluoro
- hydroxyethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 10
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 9
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 9
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 8
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 208000000172 Medulloblastoma Diseases 0.000 claims description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 8
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 8
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 8
- 229960003852 atezolizumab Drugs 0.000 claims description 8
- 229950002916 avelumab Drugs 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 229950009791 durvalumab Drugs 0.000 claims description 8
- 201000010536 head and neck cancer Diseases 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 229960003301 nivolumab Drugs 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 claims description 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 238000007911 parenteral administration Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- TUCVAXGUCJNKBE-LIRRHRJNSA-N C(CCC)(=O)N[C@H](C(=O)N[C@@H]1C(N(C2=C(C3=C1C=CC=C3)C=CC=N2)CCO)=O)C Chemical compound C(CCC)(=O)N[C@H](C(=O)N[C@@H]1C(N(C2=C(C3=C1C=CC=C3)C=CC=N2)CCO)=O)C TUCVAXGUCJNKBE-LIRRHRJNSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339363P | 2016-05-20 | 2016-05-20 | |
| US62/339,363 | 2016-05-20 | ||
| PCT/US2017/032790 WO2017200969A1 (en) | 2016-05-20 | 2017-05-16 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516733A JP2019516733A (ja) | 2019-06-20 |
| JP2019516733A5 true JP2019516733A5 (enExample) | 2020-07-02 |
| JP7194022B2 JP7194022B2 (ja) | 2022-12-21 |
Family
ID=58772978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560759A Active JP7194022B2 (ja) | 2016-05-20 | 2017-05-16 | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10688104B2 (enExample) |
| EP (1) | EP3458091B1 (enExample) |
| JP (1) | JP7194022B2 (enExample) |
| KR (1) | KR102463617B1 (enExample) |
| CN (2) | CN109475629A (enExample) |
| AU (1) | AU2017268187A1 (enExample) |
| BR (1) | BR112018073673A2 (enExample) |
| CA (1) | CA3025024A1 (enExample) |
| ES (1) | ES2904880T3 (enExample) |
| IL (1) | IL263110B (enExample) |
| MA (1) | MA45025A (enExample) |
| MX (1) | MX2018013941A (enExample) |
| SG (1) | SG11201810268YA (enExample) |
| WO (1) | WO2017200969A1 (enExample) |
| ZA (1) | ZA201807585B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| KR102418766B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| JP2021506968A (ja) * | 2017-12-18 | 2021-02-22 | デビオファーム・インターナショナル・エス・アーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． | 癌を治療するためのアゴニスト抗ＰＤ−１抗体とＧｎＲＨアゴニスト又はアンタゴニストとの併用 |
| JP2022553421A (ja) * | 2019-10-28 | 2022-12-22 | エンジーケム ライフサイエンシーズ コーポレーション | がんの処置のための方法および組成物 |
| KR20240004519A (ko) * | 2021-04-28 | 2024-01-11 | 아센타위츠 파마슈티컬즈 리미티드 | 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199901343T2 (xx) | 1996-12-23 | 1999-09-21 | Elan Pharmaceuticals, Inc. | Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| WO2000020576A2 (en) | 1998-10-02 | 2000-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health | Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) * | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| DE102006002966A1 (de) * | 2006-01-21 | 2007-07-26 | Schaeffler Kg | Laufscheibe mit integrierter Wälzkörperlaufbahn |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CN101778826B (zh) | 2007-08-14 | 2012-10-31 | 伊莱利利公司 | 作为γ分泌酶抑制剂的氮杂*衍生物 |
| MA33076B1 (fr) | 2008-01-11 | 2012-03-01 | Hoffmann La Roche | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2470054B1 (de) | 2009-08-26 | 2013-12-04 | FrXsh AG | Vorrichtung und verfahren zum mischen von mischgut |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| CA2802344C (en) * | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP2739358B1 (en) * | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
| US9827309B2 (en) * | 2013-08-20 | 2017-11-28 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| US9465158B2 (en) * | 2014-09-04 | 2016-10-11 | National Taiwan Normal University | Light-guide coupler for modulating angular and spatial distributions of light source |
| WO2016040882A1 (en) * | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| MX389823B (es) * | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| US20160176962A1 (en) * | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
| EP3872094A3 (en) | 2014-12-05 | 2021-12-08 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| EP3662909A1 (en) | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| KR102418766B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| US20190209581A1 (en) | 2016-08-31 | 2019-07-11 | Eli Lilly And Company | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-05-16 US US16/301,360 patent/US10688104B2/en active Active
- 2017-05-16 CN CN201780044786.9A patent/CN109475629A/zh active Pending
- 2017-05-16 BR BR112018073673-2A patent/BR112018073673A2/pt not_active Application Discontinuation
- 2017-05-16 CA CA3025024A patent/CA3025024A1/en active Pending
- 2017-05-16 AU AU2017268187A patent/AU2017268187A1/en not_active Abandoned
- 2017-05-16 ES ES17726073T patent/ES2904880T3/es active Active
- 2017-05-16 JP JP2018560759A patent/JP7194022B2/ja active Active
- 2017-05-16 IL IL263110A patent/IL263110B/en unknown
- 2017-05-16 MX MX2018013941A patent/MX2018013941A/es unknown
- 2017-05-16 MA MA045025A patent/MA45025A/fr unknown
- 2017-05-16 WO PCT/US2017/032790 patent/WO2017200969A1/en not_active Ceased
- 2017-05-16 KR KR1020187036486A patent/KR102463617B1/ko active Active
- 2017-05-16 SG SG11201810268YA patent/SG11201810268YA/en unknown
- 2017-05-16 EP EP17726073.4A patent/EP3458091B1/en active Active
- 2017-05-16 CN CN202211692364.1A patent/CN115845070A/zh active Pending
-
2018
- 2018-11-12 ZA ZA2018/07585A patent/ZA201807585B/en unknown
-
2020
- 2020-05-08 US US16/870,853 patent/US11826317B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2023041862A5 (enExample) | ||
| JP2022519375A5 (enExample) | ||
| IL263110B (en) | Combined treatment of notch and pd-1 or pd-l1 inhibitors | |
| JP2014512356A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| JP2019517549A5 (enExample) | ||
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| JP2019506403A5 (enExample) | ||
| JP2014509657A5 (enExample) | ||
| TW200533339A (en) | Therapeutic synergy of anti-cancer compounds | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2017536408A5 (enExample) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2020516646A5 (enExample) | ||
| JP2021512149A5 (enExample) | ||
| JP2019511529A5 (enExample) | ||
| JP6014142B2 (ja) | Ｎ−ヒドロキシ−４−｛２−［３−（ｎ，ｎ−ジメチルアミノメチル）ベンゾフラン−２−イルカルボニルアミノ］エトキシ｝ベンズアミドの投与に関するスキーム | |
| JP2019534251A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2021505669A5 (enExample) | ||
| JP2015510945A5 (enExample) | ||
| EP2344156B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent | |
| RU2021126526A (ru) | Фармацевтическая комбинация, содержащая tno155 и рибоциклиб |